Oral immunization with rotavirus VP7‑CTB fusion expressed in transgenic Arabidopsisï¿½thaliana induces antigen‑specific IgA and IgG and passive protection in mice

Li, Yuxian; Guan, Lili; Liu, Xiuming; Liu, Weican; Yang, Jing; Zhang, Xiaomei; Wang, Fawei; Guo, Yongxin; Li, Haiyan; Li, Xiaokun

doi:10.3892/etm.2018.6003

Cited by 3 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that human breast milk provides passive immunity to newborns primarily in the form of specific polyclonal SIgA [31], there is interest in replicating this phenomenon utilizing mAbs for protection against enteric pathogens. In vivo, antigen-specific oral IgA has already been shown to protect against rotavirus challenge in a suckling mouse model [32] and oral feedings of recombinant VHH-IgAs, specific for the F4 fimbriae of ETEC, to piglets prior to bacterial challenge significantly reduced disease progression compared to control-fed groups [33]. After establishing Sal4 as a superior anti-O5 mAb, we sought to investigate its potential prophylactically in a model of STm infection.…”

Section: Pre-exposure Prophylactic Activity Of Sal4 Igamentioning

confidence: 99%

Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies

et al. 2020

View full text Add to dashboard Cite

Non-typhoidal Salmonella enterica strains, including serovar Typhimurium (STm), are an emerging cause of invasive disease among children and the immunocompromised, especially in regions of sub-Saharan Africa. STm invades the intestinal mucosa through Peyer's patch tissues before disseminating systemically. While vaccine development efforts are ongoing, the emergence of multidrug resistant strains of STm affirms the need to seek alternative strategies to protect high-risk individuals from infection. In this report, we investigated the potential of an orally administered O5 serotype-specific IgA monoclonal antibody (mAb), called Sal4, to prevent infection of invasive Salmonella enterica serovar Typhimurium (STm) in mice. Sal4 IgA was delivered to mice prior to or concurrently with STm challenge. Infectivity was measured as bacterial burden in Peyer's patch tissues one day after challenge. Using this model, we defined the minimal amount of Sal4 IgA required to significantly reduce STm uptake into Peyer's patches. The relative efficacy of Sal4 in dimeric and secretory IgA (SIgA) forms was compared. To assess the role of isotype in oral passive immunization, we engineered a recombinant IgG1 mAb carrying the Sal4 variable regions and evaluated its ability to block invasion of STm into epithelial cells in vitro and Peyer's patch tissues. Our results demonstrate the potential of orally administered monoclonal IgA and SIgA, but not IgG, to passively immunize against invasive Salmonella. Nonetheless, the prophylactic window of IgA/SIgA in the mouse was on the order of minutes, underscoring the need to develop formulations to protect mAbs in the gastric environment and to permit sustained release in the small intestine.

show abstract

Section: Pre-exposure Prophylactic Activity Of Sal4 Igamentioning

confidence: 99%

Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interestingly, given the structural similarity between orbiviruses and human and animal rotaviruses (RVs; all members of family Reoviridae ; all with dsRNA genomes and four capsid proteins), and the fact that people have been expressing RV proteins in plants since at least 2001 (Yu & Langridge, ), it is surprising that very few studies report the expression or more than one protein (generally VP6 or VP7; Choi, Estes, & Langridge, ; Dong, Liang, Jin, Zhang, & Wang, ; Gonzalez et al, ; J. T. Li et al, , p. 546; Y. Li et al, ) or the formation of VNPs. Two that do report particle formation in plants did so only for VP2 and VP6 expression in transgenic tomatoes (Saldana et al, ), and via transient expression in N. benthamiana (Pera et al, ): while particles were immunogenic, there was no evidence of protection from infection.…”

Section: Animal Virus‐derived Vnpsmentioning

confidence: 99%

Plant molecular farming of virus‐like nanoparticles as vaccines and reagents

Rybicki

2019

WIREs Nanomed Nanobiotechnol

101

View full text Add to dashboard Cite

The use of plants for the production of virus‐like nanoparticles (VNPs) dates back to separating natural empty capsids of plant viruses from whole virions nearly 70 years ago, through to the present use of transgenic plants or recombinant Agrobacterium tumefaciens and/or plant virus‐derived vectors for the transient expression of engineered viral or other structural proteins in plants—a production system also known as molecular farming. Plant production of heterologous proteins has major advantages in terms of convenience—whole plants are generally used, and processes do not need to be sterile—and cost, as bulk biomass production is significantly cheaper than by any other method. Plant‐made VNPs in current use for nanotechnology include whole virions and naturally occurring empty capsids of plant viruses, and particles made by reassembly of coat protein (CP) purified from virions or by recombinant expression. Engineered VNP‐forming animal or human virus CPs expressed in plants include L1 protein from human papillomaviruses, human norovirus CP, hepatitis B surface and core antigens, influenza virus HA protein and HIV Gag polyprotein forming large enveloped particles by budding, orbi‐ and rotavirus particles that require assembly of four co‐expressed proteins, and polio‐ and foot and mouth disease viruses which require proteolytic processing of a polyprotein precursor to form 4‐component VNPs. Both plant and animal virus‐derived plant‐made VNPs can be used for surface and internal display of heterologous peptides or even whole proteins. A significant recent development has been the production of pseudovirions in plants, comprising plant or animal virus CPs and RNA or DNA pseudogenomes that can be used to deliver nucleic acid payloads into cultured cells or specific tissues or tumors in whole animals. This article is characterized under: Biology‐Inspired Nanomaterials > Protein and Virus‐Based Structures Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > in vivo Nanodiagnostics and Imaging

show abstract

“…In order to overcome aforementioned issues, the present study involved the prediction of T-cell epitopes using linear B-cell epitopes as input instead of whole antigen so as to minimize not only the size of PV but also elicit both cellular (T-cell epitope) as well as humoral (B-cell epitope) immune responses. Further, the non toxic nature of adjuvants A and B also helps in production of several cytokines (e.g., INF-γ, TNF-α, IL-2, IL-4, IL-6, IL-12) through induction of dendritic cell, B-cell, macrophage and T-cell, which ultimately boost the concentration of the antibodies reported in several studies linked to various disease causing agents including human rotavirus, HIV, Helicobacter pylori, Influenza virus [76][77][78][79]. Therefore, 15 PVs were designed through epitope ensemble of Tcell epitopes and/or linear B-cell epitopes having epitope ensemble with different linkers as well as adjuvants, which are responsible for the activation of TLR2 and TLR4 receptors pertaining to malaria.…”

Section: Design Of Pvs For Malariamentioning

confidence: 99%

A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria

Pritam

Singh

Swaroop

et al. 2020

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Human malaria is a pathogenic disease mainly caused by Plasmodium falciparum, which was responsible for about 405,000 deaths globally in the year 2018. To date, several vaccine candidates have been evaluated for prevention, which failed to produce optimal output at various preclinical/clinical stages. This study is based on designing of polypeptide vaccines (PVs) against human malaria that cover almost all stages of life-cycle of Plasmodium and for the same 5 genome derived predicted antigenic proteins (GDPAP) have been used. For the development of a multi-immune inducer, 15 PVs were initially designed using T-cell epitope ensemble, which covered N99% human population as well as linear B-cell epitopes with or without adjuvants. The immune simulation of PVs showed higher levels of T-cell and B-cell activities compared to positive and negative vaccine controls. Furthermore, in silico cloning of PVs and codon optimization followed by enhanced expression within Lactococcus lactis host system was also explored. Although, the study has sound theoretical and in silico findings, the in vitro/in vivo evaluation seems imperative to warrant the immunogenicity and safety of PVs towards management of P. falciparum infection in the future.

show abstract

Oral immunization with rotavirus VP7‑CTB fusion expressed in transgenic Arabidopsisï¿½thaliana induces antigen‑specific IgA and IgG and passive protection in mice

Cited by 3 publications

References 47 publications

Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies

Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies

Plant molecular farming of virus‐like nanoparticles as vaccines and reagents

A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria

Contact Info

Product

Resources

About